Gliflozins in the Management of Cardiovascular Disease

N Engl J Med. 2022 Aug 4;387(5):477-478. doi: 10.1056/NEJMc2208130.

Authors

Samuel N Heyman¹, Zaid Abassi²

Affiliations

¹ Hadassah Hebrew University Hospital, Jerusalem, Israel.
² Technion Israel Institute of Technology, Haifa, Israel samuel.heyman@mail.huji.ac.il.

PMID: 35921467
DOI: 10.1056/NEJMc2208130

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors